Day One Biopharmaceuticals, Inc.DAWNNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank83
3Y CAGR+20.1%
5Y CAGR+74.7%
Year-over-Year Change
Research and development spending
3Y CAGR
+20.1%/yr
Annual compound
5Y CAGR
+74.7%/yr
Recent deceleration
Percentile
P83
Within normal range
vs 5Y Ago
16.3x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $148.13M | -34.9% |
| 2024 | $227.70M | +74.5% |
| 2023 | $130.52M | +52.4% |
| 2022 | $85.62M | +96.4% |
| 2021 | $43.58M | +378.9% |
| 2020 | $9.10M | -34.5% |
| 2019 | $13.90M | - |